Tyra Biosciences (NASDAQ:TYRA) Issues Quarterly Earnings Results

Tyra Biosciences (NASDAQ:TYRA) posted its quarterly earnings results on Tuesday. The company reported ($0.69) EPS for the quarter, missing the consensus estimate of ($0.67) by ($0.02), Zacks reports.

Tyra Biosciences Stock Up 1.5%

NASDAQ:TYRA traded up $0.49 during trading hours on Tuesday, reaching $32.53. 347,643 shares of the company’s stock were exchanged, compared to its average volume of 910,415. Tyra Biosciences has a 1-year low of $9.96 and a 1-year high of $40.65. The firm has a market capitalization of $1.93 billion, a price-to-earnings ratio of -14.92 and a beta of 0.77. The company has a 50-day moving average of $30.47 and a 200 day moving average of $32.71.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Commodore Capital LP increased its stake in Tyra Biosciences by 226.3% in the 2nd quarter. Commodore Capital LP now owns 3,100,000 shares of the company’s stock valued at $29,667,000 after buying an additional 2,150,000 shares during the period. Janus Henderson Group PLC boosted its holdings in shares of Tyra Biosciences by 2.1% in the fourth quarter. Janus Henderson Group PLC now owns 2,935,442 shares of the company’s stock valued at $77,085,000 after acquiring an additional 60,638 shares in the last quarter. Farallon Capital Management LLC increased its stake in shares of Tyra Biosciences by 80.7% during the fourth quarter. Farallon Capital Management LLC now owns 2,066,818 shares of the company’s stock worth $54,337,000 after acquiring an additional 923,000 shares during the period. Vanguard Group Inc. increased its stake in shares of Tyra Biosciences by 8.5% during the third quarter. Vanguard Group Inc. now owns 1,520,185 shares of the company’s stock worth $21,267,000 after acquiring an additional 118,492 shares during the period. Finally, Caligan Partners LP raised its holdings in Tyra Biosciences by 35.5% during the fourth quarter. Caligan Partners LP now owns 944,257 shares of the company’s stock worth $24,825,000 after purchasing an additional 247,432 shares in the last quarter. 84.14% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on TYRA. Guggenheim began coverage on shares of Tyra Biosciences in a research report on Tuesday, April 14th. They set a “buy” rating and a $54.00 price objective for the company. HC Wainwright reissued a “buy” rating and issued a $45.00 target price on shares of Tyra Biosciences in a report on Thursday, May 14th. Canaccord Genuity Group assumed coverage on Tyra Biosciences in a research note on Monday, April 6th. They issued a “buy” rating and a $50.00 price target on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Tyra Biosciences in a report on Friday, July 17th. Finally, Bank of America upped their price objective on Tyra Biosciences from $37.00 to $42.00 and gave the stock a “buy” rating in a research report on Wednesday, June 10th. One research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Tyra Biosciences has a consensus rating of “Moderate Buy” and a consensus target price of $47.00.

Tyra Biosciences Company Profile

Tyra Biosciences (NASDAQ: TYRA) is a clinical-stage precision oncology company focused on the discovery and development of small-molecule therapies for genetically defined cancers. The company integrates bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors. By leveraging large-scale genomic datasets and functional screening, Tyra Biosciences aims to advance therapies that address patient populations with high unmet medical need.

The company’s pipeline includes multiple programs at various stages of development, each directed against distinct molecular vulnerabilities in cancer cells.